Bridger Management, LLC Nektar Therapeutics Transaction History

Bridger Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $18.3 Million - $39.3 Million	-1,083,598 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$31.0 - $36.3 $4.8 Million - $5.62 Million	-154,891 Reduced 12.51%	1,083,598 $38.6 Million
Q1 2019 May 15, 2019	BUY	$31.58 - $46.35 $3.29 Million - $4.82 Million	104,075 Added 9.17%	1,238,489 $41.6 Million
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $21.5 Million - $48.7 Million	465,922 Added 69.7%	1,134,414 $55.4 Million
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $40.1 Million - $75.8 Million	-698,679 Reduced 51.1%	668,492 $71 Million
Q4 2017 Feb 14, 2018	SELL	$23.02 - $60.5 $20.9 Million - $54.9 Million	-907,490 Reduced 39.9%	1,367,171 $81.6 Million
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $40.5 Million - $54.6 Million	2,274,661	2,274,661 $54.6 Million

153

131M

92.7K

4.9K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $163M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Bridger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridger Management, LLC with notifications on news.